ArticleEClinicalMedicine2023

Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial.

Gernot Rohde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.